AbCellera Biologics Inc. (NASDAQ:ABCL) shares fell to a low of $32.06 before closing at $32.56. Intraday shares traded counted 0.8 million, which was 26.67% higher than its 30-day average trading volume of 1.09M. ABCL’s previous close was $32.62 while the outstanding shares total 269.70M. The firm has a 12-month trailing P/E ratio of 135.10. The stock’s Relative Strength Index (RSI) is 55.05, with weekly volatility at 4.79% and ATR at 2.21. The ABCL stock’s 52-week price range has touched low of $23.20 and a $71.91 high. The stock traded lower over the last trading session, losing -0.18% on 05/25/21.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Investors have identified the Biotechnology company AbCellera Biologics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $8.76 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Having a look at the company’s valuation, the company is expected to record -0.14 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on ABCL sounds very interesting.
Is the stock of ABCL attractive?
In the last 6 months, insiders have changed their ownership in shares of company stock by 23.30%.
5 out of 5 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on AbCellera Biologics Inc.. 0 analysts has assigned a Sell rating on the ABCL stock. The 12-month mean consensus price target for the company’s shares has been set at $51.20.
